TY - JOUR
T1 - Arginase 1
T2 - An unexpected mediator of pulmonary capillary barrier dysfunction in models of acute lung injury
AU - Lucas, Rudolf
AU - Czikora, Istvan
AU - Sridhar, Supriya
AU - Zemskov, Evgeny Alexandrovich
AU - Oseghale, Aluya
AU - Circo, Sebastian
AU - Cederbaum, Stephen D.
AU - Chakraborty, Trinad
AU - Fulton, David J
AU - Caldwell, Robert William
AU - Romero Lucas, Maritza Josefina
PY - 2013
Y1 - 2013
N2 - The integrity of epithelial and endothelial barriers in the lower airspaces of the lungs has to be tightly regulated, in order to prevent leakage and to assure efficient gas exchange between the alveoli and capillaries. Both G- and G+ bacterial toxins, such as lipopolysaccharide and pneumolysin, respectively, can be released in high concentrations within the pulmonary compartments upon antibiotic treatment of patients suffering from acute respiratory distress syndrome (ARDS) or severe pneumonia. These toxins are able to impair endothelial barrier function, either directly, or indirectly, by induction of pro-inflammatory mediators and neutrophil sequestration. Toxin-induced endothelial hyperpermeability can involve myosin light chain phosphorylation and/or microtubule rearrangement. Endothelial nitric oxide synthase (eNOS) was proposed to be a guardian of basal barrier function, since eNOS knock-out mice display an impaired expression of inter-endothelial junction proteins and as such an increased vascular permeability, as compared to wild type mice. The enzyme arginase, the activity of which can be regulated by the redox status of the cell, exists in two isoforms-arginase 1 (cytosolic) and arginase 2 (mitochondrial)-both of which can be expressed in lung microvascular endothelial cells. Upon activation, arginase competes with eNOS for the substrate l-arginine, as such impairing eNOS-dependent NO generation and promoting reactive oxygen species generation by the enzyme. This mini-review will discuss recent findings regarding the interaction between bacterial toxins and arginase during acute lung injury and will as such address the role of arginase in bacterial toxin-induced pulmonary endothelial barrier dysfunction.
AB - The integrity of epithelial and endothelial barriers in the lower airspaces of the lungs has to be tightly regulated, in order to prevent leakage and to assure efficient gas exchange between the alveoli and capillaries. Both G- and G+ bacterial toxins, such as lipopolysaccharide and pneumolysin, respectively, can be released in high concentrations within the pulmonary compartments upon antibiotic treatment of patients suffering from acute respiratory distress syndrome (ARDS) or severe pneumonia. These toxins are able to impair endothelial barrier function, either directly, or indirectly, by induction of pro-inflammatory mediators and neutrophil sequestration. Toxin-induced endothelial hyperpermeability can involve myosin light chain phosphorylation and/or microtubule rearrangement. Endothelial nitric oxide synthase (eNOS) was proposed to be a guardian of basal barrier function, since eNOS knock-out mice display an impaired expression of inter-endothelial junction proteins and as such an increased vascular permeability, as compared to wild type mice. The enzyme arginase, the activity of which can be regulated by the redox status of the cell, exists in two isoforms-arginase 1 (cytosolic) and arginase 2 (mitochondrial)-both of which can be expressed in lung microvascular endothelial cells. Upon activation, arginase competes with eNOS for the substrate l-arginine, as such impairing eNOS-dependent NO generation and promoting reactive oxygen species generation by the enzyme. This mini-review will discuss recent findings regarding the interaction between bacterial toxins and arginase during acute lung injury and will as such address the role of arginase in bacterial toxin-induced pulmonary endothelial barrier dysfunction.
KW - Arginase 1
KW - Capillary leak
KW - Endothelial nitric oxide synthase
KW - Pneumolysin
KW - Pneumonia
UR - http://www.scopus.com/inward/record.url?scp=84883663145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883663145&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2013.00228
DO - 10.3389/fimmu.2013.00228
M3 - Article
C2 - 23966993
AN - SCOPUS:84883663145
SN - 1664-3224
VL - 4
JO - Frontiers in immunology
JF - Frontiers in immunology
IS - AUG
M1 - Article 228
ER -